Yao Yingsha, Zhu Shulan, Zhu Xiaoming
Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Hangzhou Linping District Maternal & Child Health Care Hospital, Hangzhou 311199, China.
Diagnostics (Basel). 2024 Dec 20;14(24):2872. doi: 10.3390/diagnostics14242872.
Endometrial proliferative lesions (EPLs) encompass endometrial hyperplasia (EH) and endometrial carcinoma (EC). Atypical endometrial hyperplasia (AEH) is associated with an elevated risk of progression to EC. Patients with polycystic ovarian syndrome (PCOS) exhibit higher serum levels of anti-Müllerian hormone (AMH) and a correspondingly increased incidence of EPLs. AMH has the capacity to inhibit the cell proliferation of EPLs derived from Müllerian duct tissue through the AMH-AMH receptor (AMHR) signaling pathway.
Pairs of samples matched by preference scores were randomly selected. Immunohistochemistry was employed to assess the expression levels of AMHR type II (AMHR2) in endometrial tissue. A comparative analysis was performed between tissues from individuals with PCOS and those without, as well as between a normal endometrium and endometrial tissue from individuals with EPLs. This study aimed to elucidate differences in AMHR2 expression among these tissue types. By focusing on AMHR2 expression, the impact of the PCOS-related background on the endometrial AMH-AMHR cascade signaling pathway was initially investigated.
The AMHR2 protein was expressed in the endometrium of both the PCOS group and the non-PCOS group during the reproductive age (20-39 years). The expression of the AMHR2 protein in the AEH endometrium of PCOS patients did not differ significantly from that in the normal endometrium of PCOS patients; however, it was significantly higher than in the AEH endometrium of non-PCOS patients ( = 0.011). Conversely, the expression of the AMHR2 protein in the AEH endometrium of non-PCOS patients was significantly lower than that in the normal endometrium of non-PCOS patients ( = 0.021). Notably, there was no significant difference in AMHR2 protein expression in a normal endometrium between PCOS and non-PCOS patients.
The involvement of the endometrial AMH-AMHR cascade signaling pathway and its biological effects in the pathogenesis of AEH are evident. The pathophysiological conditions associated with PCOS, such as elevated serum AMH levels and other pathological states, may directly or indirectly influence the AMH-AMHR cascade signaling pathway in the endometrium. This influence could contribute to the progression of AEH.
子宫内膜增生性病变(EPLs)包括子宫内膜增生(EH)和子宫内膜癌(EC)。非典型子宫内膜增生(AEH)与进展为EC的风险升高相关。多囊卵巢综合征(PCOS)患者血清抗苗勒管激素(AMH)水平较高,相应地EPLs发病率增加。AMH能够通过AMH-AMH受体(AMHR)信号通路抑制源自苗勒管组织的EPLs细胞增殖。
通过偏好评分匹配的样本对被随机选择。采用免疫组织化学法评估子宫内膜组织中II型AMHR(AMHR2)的表达水平。对PCOS患者和非PCOS患者的组织以及正常子宫内膜与EPLs患者的子宫内膜组织进行了比较分析。本研究旨在阐明这些组织类型中AMHR2表达的差异。通过关注AMHR2表达,初步研究了PCOS相关背景对子宫内膜AMH-AMHR级联信号通路的影响。
在生殖年龄(20 - 39岁),PCOS组和非PCOS组的子宫内膜均表达AMHR2蛋白。PCOS患者AEH子宫内膜中AMHR2蛋白的表达与PCOS患者正常子宫内膜中的表达无显著差异;然而,它显著高于非PCOS患者的AEH子宫内膜中的表达( = 0.011)。相反,非PCOS患者AEH子宫内膜中AMHR2蛋白的表达显著低于非PCOS患者正常子宫内膜中的表达( = 0.021)。值得注意的是,PCOS患者和非PCOS患者正常子宫内膜中AMHR2蛋白表达无显著差异。
子宫内膜AMH-AMHR级联信号通路及其生物学效应在AEH发病机制中的参与是明显的。与PCOS相关的病理生理状况,如血清AMH水平升高和其他病理状态,可能直接或间接影响子宫内膜中的AMH-AMHR级联信号通路。这种影响可能促成AEH的进展。